The reason for that seems to be that a low DNR accumulation may not be the most important factor in determining the LC 50 . While the clinical usefulness of these drug resistance tests remains to be proven they do not seem to provide as yet a straightforward explanation for the major cause(s) of clinical chemotherapy failure.
Introduction
Resistance to chemotherapy remains an important obstacle for effective treatment of acute myeloid leukemia (AML). Although 60 to 70% of patients with de novo AML achieve a complete remission, the great majority of these patients will relapse and eventually die of their disease. Thus failure to treatment includes the occurrence of initial resistance to induction therapy, as well as secondary resistance to chemotherapy after relapse. Laboratory assays with a robust endpoint, that would accurately predict response or lack of response to single agent or combinations of anti-cancer drugs are not available for routine use. 1 Several in vitro tests measuring cell proliferation or (drug-induced) cell death have been proposed as prognostic indicators for AML. Among these are the differential staining cytoxicity test, 2, 3 in vitro autonomous proliferation 4 and the 'MTT' chemosensitivity test. 5, 6 The latter test has been applied to predict the clinical response to combination therapy in childhood lymphoblastic leukemia. 6, 7 In adult leukemias, including AML, more effort has been put into the application of mechanism-based drug resistance tests. As far as the anthracyclines are concerned, tests which measure the intracellular accumulation of the anthracycline in patients' myeloblasts have been initially explored. However, negative or inconsistent results were reported early on with respect to the correlation of in vivo, 8 as well as in vitro uptake 9,10 of daunorubicin (DNR) into blasts with respect to clinical outcome. Before definitive conclusions on the value of this type of assay could be drawn, these tests were in their turn superseded by attempts to devise assays for the presence or function of the multidrug transporter protein, the MDR1 encoded Pglycoprotein (Pgp), which is responsible for the multidrug resistance (MDR) phenotype of many in vitro anthracyclineselected tumor cell lines. A variety of different methods has been used with varying success to establish a correlation between the expression of Pgp and clinical outcome of AML. [11] [12] [13] Still the question whether the Pgp-mediated efflux of DNR or other drugs out of leukemic cells is a major contributor to the in vivo antitumor effect of combination chemotherapy or even to the in vitro cytotoxicity of the drug has not been answered. 14 The answer to these questions might be important to understand the relative contribution of Pgp to clinical treatment failure and for the proper planning of clinical trials with Pgp inhibitors or alternative therapies.
Many factors may contribute to the difficulty in obtaining quantitative data on the relation of Pgp expression with drug cytotoxicity. One problem relates to the correct measurement of P-glycoprotein or its pumping activity in patient cells, which despite considerable effort, including at least three multicenter studies has not been solved definitively. [15] [16] [17] A second problem is the lack of an established, validated cytotoxicity test which has proven to be predictive of clinical response in AML. Such a test would allow determination of the net effect of Pgp expression on drug resistance by measuring the cytotoxicity of a drug such as DNR with and without the presence of an agent that completely inhibits Pgpmediated DNR efflux. All the contributions to a round-table debate on MDR analysis, published in Leukemia in July 1997, address the first question (Pgp determination), except one paper by Efferth et al. 18 These authors used an MTT assay in order to find evidence for or against a contribution of Pgp to the cytotoxicity of daunorubicin (DNR) in AML. The authors concluded that a low proliferative activity (S phase fraction) as well as low 'spontaneous cell death' (percentage apoptotic cells as measured with propidium iodide staining) correlated better with DNR cytotoxicity than Pgp-related parameters (modulation of DNR accumulation by cyclosporin A). As a further contribution to the development of predictive assays for clinical efficacy of anthracycline-based chemotherapy we have used an MTT assay according to the same methodology 7, 19 in AML to determine DNR cytotoxicity with or without the Pgp modulator PSC 833. This test was compared with a rhodamine-based Pgp functional assay, as well as a DNR accumulation assays. In addition we address the question whether two other proteins that have been implicated in MDR in AML, namely the major vault protein (Mvp/LRP) 20, 21 and the multidrug resistance protein (MRP1) 22 correlate with DNR accumulation and/or DNR LC 50 .
Materials and methods

Cell lines
Wild-type KB3-1 human epidermoid carcinoma cells and its Pgp-overexpressing variants, KB8 and KB8-5, were used throughout these studies to monitor the sensitivity of Pgp expression (MRK16 labelling) and transport function (rhodamine/PSC833) assays as described earlier.
14,16 SW-1573 and SW-1573/2R120, GLC 4 and GLC 4 /ADR lung carcinoma cell lines are used as controls for the detection of LRP and MRP1.
Clinical samples
Peripheral blood or bone marrow from acute myeloid leukemia patients (age at diagnosis: mean 44, median 45, range 15.6-78.2 years) was collected in heparinized glass tubes before treatment. Mononuclear cells were isolated on Lymphoprep (Ficoll-Paque; Pharmacia LKB, Uppsala, Sweden) by centrifugation for 25 min at 150 g. Interphase cells were washed and resuspended in assay medium (Dulbecco's modified Eagle's medium with 20 mm Hepes (pH = 7.4 at 37°C) and 10% fetal calf serum). Samples with Ͼ80% blast cells were used for this study. Samples were stored on ice when analyzed the same day (within 6 h at most) or frozen in liquid nitrogen in medium containing 10% fetal calf serum and 10% DMSO. We have shown before that at least the rhodamine 123/PSC 833 test can be done using thawed AML samples. 16 
Flow cytometric P-glycoprotein and MRP1 detection
Pgp expression was measured by labeling viable cells with the MRK-16 monoclonal antibody and FITC-labeled second antibody and analysis of fluorescence on a FACS Calibur, as described before. 16 Events were collected from a gate containing blast cells as determined by scatter characteristics. Data are expressed as the ratio of the mean fluorescence of MRK16 divided by isotype control antibody-labelled cells ('PGPMRK 16'). MRP1 was measured by labeling cells with the MRPr1 antibody after permeabilization with ice-cold 2% formalin solution in acetone as described before. 23 Data are expressed as the ratio of the mean fluorescence of MRPr1 divided by isotype control antibody-labeled cells ('MRPMRPr1').
Flow cytometric P-glycoprotein activity assay
Freshly isolated or in some cases thawed leukemic samples (after thawing preincubated for 60 min in medium containing 40% FCS) were incubated for 75 min at 37°C in assay medium with 2 mol/l DNR or 200 ng/ml rhodamine 123 (Sigma, St Louis, MO, USA) with or without 2 mol/l PSC 833 (Novartis, Basle, Switzerland) and after washing the cells with cold assay medium, the fluorescence was measured exactly as described before 16 in blast cells gated by scatter characteristics. The results are expressed as the ratio of the mean fluorescence or RHO or DNR labeled cells in the presence of PSC833 divided by cells labelled in the absence of PSC833 ('RHOratio' and 'DNRratio').
Radioactive daunorubicin accumulation
The accumulation of 3 H-labeled DNR after 75 min incubation at 37°C in assay medium, containing 0.005% DNAseI (Boehringer, Mannheim, Germany) was always measured using freshly isolated cells. Mean cell diameters were determined with an Elzone type 80XY Electronezone/Celloscope (Particle Data, Elmhurst, IL, USA). The radioactive DNR accumulation was corrected for cell volume (corresponding to the mean of the values found for the AML populations: л = 8.86 m). The use of this method to determine absolute values of intracellular DNR accumulation has been described in detail before for cell lines, as well as leukemic samples. 21, 24 Data are expressed as DNR accumulation in pmol/10 6 cells ('DNRacc').
LRP immunocytochemistry
Cells were cytocentrifuged, dried and fixed for 10 min with ice-cold acetone and stored at −20°C. After thawing cytospins were fixed again for 1 min with ice-cold acetone. Staining was done with a double APAAP as described 23 with LRP56 or irrelevant control antibody (2 g/ml; 60 min, room temperature) as first step. Scoring was done independently by two observers and staining was compared with control cell lines SW-1573 and SW-1573/2R120 stained simultaneously, which express levels of LRP of 1+ and 4+, respectively. AMLs were scored from 0 to 4+, where a score of 0 means all cells negative, 1+ means Ͻ10% of the cells showing some positivity and 2+, 3+ and 4+ Ͼ10% positive cells of increasing intensity. In most of these cases the great majority of the cells stained. Data were also analyzed by taking groups 0 and 1 as LRP-negative and 2, 3 and 4 as LRP-positive, because this might be a more meaningful distinction. AMLs stained with control antibody were negative in every case.
MTT cytotoxicity test
The MTT test was performed exactly as described earlier. 6, 7, 19 Briefly, cells were incubated in microtiter plates for 4 days with six DNR concentrations (0.002-2 g/ml) in duplicate wells. Results are expressed as DNR LC 50 values: the DNR concentration lethal to 50% of the cells as compared to cells from the same sample cultured in the same plate without DNR. Fresh as well as frozen/thawed samples were used, which had been validated previously. 7, 19 Samples, which had on day 4 a blast percentage Ͼ70% and an OD of 50 or higher were included. The DNR cytotoxicity was also tested in the presence of the Pgp inhibitor PSC833 (2 mol/l), which itself was not toxic to the cells under these conditions (OD was 80-110% of untreated controls). The PSC 833 effect is expressed as the ratio of the DNR LC 50 s without and with PSC833.
The percentage of evaluable tests is 75% of fresh samples (5% had a too low blast percentage at the start of the experiment, 20% of the samples had a too low blast percentage on day 4). After thawing the percentage of successful tests is 60%.
Statistics
Correlations between continuous variables were calculated with Spearman's rank correlation test (r s ). Correlations between LRP56 immunocytochemical staining and other parameters were analyzed with a Kruskal-Wallis test for Kindependent variables.
Results
All measured parameters
A summary of the measurements performed in this study are given in Table 1 . The different number of measurements done for each individual assay are related to priorities in experiments if time-constraints were a limiting factor and are not related to any selection based on the patient samples. Since the major purpose of this study was to determine the potential contribution of Pgp activity and LRP expression to the in vitro DNR accumulation and cytotoxicity in an MTT assay, those assays received priority. The MRP1 protein received less priority because initial data showed that our assays for MRP protein expression and function were not as sensitive as Pgp function and LRP immunocytochemistry and consequently were not expected to detect small differences in expression reliably. 23 
Pgp activity
Previous studies have shown that a flow cytometric determination of the ratio of rhodamine 123 uptake in the presence and absence of PSC 833 ('RHOratio') was a sensitive and specific test for the Pgp function in leukemic blasts, which correlated well with the PSC833 effect on DNR accumulation (DNRratio) as well as the Pgp expression as measured with MRK16. 14, 16 This was confirmed in the present group of untreated AMLs (RHOratio vs DNRratio (n = 140): r s = 0.51, (P Ͻ 0.0001); RHOratio vs PGPMRK16 (n = 134): r s = 0.50, (P Ͻ 0.0001)). For this reason and the reasons discussed extensively before, 14, 16 we regard the RHOratio parameter as the 'gold standard' for Pgp activity to which other parameters are compared. Eighty-seven percent of the RHOratio values were below 2.0 and 97% below 3.0. This means that a very high Pgp activity (RHOratio above 3.0, corresponding to a PGPMRK16 value of about 5 and an increase of more than 30% of DNR accumulation by PSC833 14 ) is only present in a small percentage of de novo AML.
In order to determine the potential contribution of Pgp activity to the in vitro resistance of AML to DNR, the RHOratio is compared to the DNR accumulation and the DNR LC 50 with or without PSC833. Figures 1 and 2 show that the RHOratio does neither correlate with the DNR LC50 (Figure 1 ) nor with the modulation of DNR LC 50 by PSC833 (Figure 2) . The same holds for Pgp Relation between the modulation of the uptake of rhodamine 123 (200 ng/ml) by 2 m PSC833 and the LC 50 of DNR (g/ml) by an in vitro MTT assay in AML.
Correlation of Pgp activity with DNR cytotoxicity
Figure 2
Relation between the modulation of the uptake of rhodamine 123 (200 ng/ml) by 2 m PSC833 and the modulation of the in vitro LC 50 of DNR (g/ml) by 2 m PSC833 in AML. expression (PGPMRK16) and DNR LC 50 (P = 0.88; not shown) or modulation of LC 50 (P = 0.07; not shown). Thus Pgp activity does not seem to be a major determinant for the in vitro DNR cytotoxicity in de novo AML as measured with an MTT assay. Nevertheless a rather high modulation of DNR LC 50 by PSC833 is seen in some AMLs (up to a factor 5) which apparently cannot be correlated with the inhibition of Pgp activity.
Correlation of Pgp activity with DNR accumulation
In order determine whether the increased Pgp activity in AML translates into a decreased DNR accumulation as is the case in in vitro selected MDR cell lines, in a subgroup of AMLs we measured the relation of Pgp activity with absolute DNR accumulation in pmol/10 6 cells. Figure 3 shows that a significant negative correlation was seen between Pgp activity and DNR accumulation. Also if the two samples with the highest Pgp activity were omitted the correlation was significant (r s = −0.44, P = 0.005; n = 38). This points to a measurable contribution of Pgp activity to the low DNR accumulation (30-50 pmol) in certain AMLs. However, as can been seen from Figure 3 a low DNR accumulation level can also occur in low Pgp expressers. In addition, there was no apparent correlation between DNR LC 50 and DNR accumulation (Figure 4 ). These data suggest that the lack of correlation between Pgp activity and DNR LC 50 might be explained by the fact that other cellular properties than the net cellular DNR uptake contribute significantly to the in vitro DNR sensitivity in de novo AML.
Correlation of MRP1 expression with DNR accumulation
In contrast to Pgp activity the MRP1 expression did not correlate with DNR accumulation (r s = −0.338, P = 0.124; n = 22) nor did the summation of Pgp activity +MRP1 correlate better with DNR accumulation (r s = −0.500, P = 0.018; n = 22) than Pgp activity or expression alone. A weak correlation was seen between the MRP1 expression and Pgp expression (PGPMRK16: r s = 0.285, P = 0.017; n = 70) but no correlation
Figure 4
Relation between the steady-state DNR accumulation (pmol/million cells) after incubation with 0.5 m DNR and the in vitro LC 50 of DNR (g/ml) of AML.
was seen between RHOratio and MRP1 expression (r s = 0.058, P = 0.633; n = 70), excluding a major contribution of this protein to the measured effect of PSC833 on RHO accumulation. Although the MRP1 data are rather limited they do not point to a prominent role of MRP1 in the intracellular pharmacology of DNR in de novo AML.
Mvp/LRP expression
Another protein associated with certain drug-resistant tumor cell lines and found to be predictive for therapy response in AML in a number of studies is the Mvp/LRP protein. Therefore, we have included this protein in the present study in order to obtain evidence for a role of Mvp/LRP in intracellular DNR pharmacology in AML. Since for Mvp there is no function known as yet and hence no functional assay is available, we have focused on the detection of the protein. In initial experiments using the cell lines SW-1573 and GLC4 as low and SW-1573/2R120 and GLC4/ADR as high Mvp/LRP expressers, we determined that flow cytometric detection would probably not be sensitive enough to detect small differences in expression reliably. Since Mvp immunocytochemistry with LRP56 showed in the great majority of cases a clear intracellular, vesicular staining pattern or a clear negative result, immunocytochemical detection of Mvp/LRP was chosen in this study. This was in contrast to our previous experience with immunocytochemical staining for Pgp in AML, which in our hands did not give unambiguous and reproducible plasma membrane staining. Since because of time constraints we have chosen not to give priority to an extensive comparison of both detection methods for Mvp/LRP in AML this study does not focus on that point.
Correlation of Pgp activity with Mvp/LRP expression
First we determined whether AMLs with high Pgp activity are the same population as high LRP expressers. Both parameters were compared in 127 patients. Figure 5 shows that a significant negative correlation (P = 0.030; Kruskal-Wallis test) was found: the highest LRP staining was present in AML with low Pgp activity. Using a score of Mvp/LRP of negative (0 + 1) or
Figure 5
Relation between the modulation of the uptake of rhodamine 123 (200 ng/ml) by 2 m PSC833 and the LRP staining (0-4+) of AML. A Kruskal-Wallis test revealed a mean rank of 72.7, 72.4, 63.9, 51.5 and 44.9 for the LRP groups 0 to 4 respectively, with a P = 0.03 (number of samples = 127). positive (2 + 3 + 4) showed a P = 0.002. To determine how much this relation was influenced by the small number of samples with high Pgp activity, the five samples with RHOratio Ͼ3.0 were omitted (3.01, 3.10, 3.70, 3,90 and 4.16) and the data were analyzed again. In this case the significance of the correlation was P = 0.043 (n = 122). The comparison of Pgp activity with LRP negative and positive scores again showed a significant difference (P = 0.003; n = 122).
Correlation of Mvp/LRP expression with DNR accumulation and cytotoxicity
To investigate if Mvp/LRP expression might have an effect on DNR accumulation in AML the relation between both parameters was calculated. From Figure 6 it can be seen that there was no relationship between both parameters. Similarly Mvp/LRP staining was not predictive for the DNR LC 50 (Figure 7 ).
Discussion
It has been suggested by many studies using a variety of different techniques, that overexpression of MDR1/Pgp in AML is
Figure 7
Relation between the in vitro LC 50 of DNR (g/ml) and the LRP staining (0-4+) of AML (Kruskal-Wallis test, P = 0.627; number of samples = 70). associated with a low complete remission rate after daunorubicin-containing induction therapy. 11, 12, 25 This is despite considerable disagreement about optimal detection methods and the way to define thresholds for overexpression. 17, 26 The general notion that Pgp expression may have a detrimental effect on the outcome of chemotherapy treatment of AML has lead to current phase III clinical trials with the Pgp function blockers cyclosporin A and PSC833 in order to test the hypothesis that Pgp blockade may improve clinical outcome in this disease.
Since there are few quantitative data, which may provide insight into the actual impact of Pgp expression on the accumulation of cytotoxic drugs such as DNR and in particular on the cytotoxic effect of these drugs on AML blasts, we have measured these parameters focusing on DNR in a series of de novo adult AML. Thus the major focus of this study is to define the contribution of MDR1/Pgp expression to chemotherapy resistance in AML more quantitatively.
Rationale for the methodology
Although we have measured in this study a large number of parameters in the same clinical specimens, we also had to make some choices at the onset of the study. Firstly, the measurement of RHOratio was taken as a standard for Pgp activity, based on our previous work. 14, 16 Second, although the modulation of DNR accumulation by PSC833 can be measured reproducibly on a flow cytometry we have chosen a radioactive assay to measure the absolute intracellular DNR accumulation. Based on ample experience with this technique in cell lines and AMLs 21, 23, 24 we considered this technique less prone to experimental errors than fluorescence-based DNR accumulation measurements. Although, the latter may have the advantage of the use of a flow cytometer, it is difficult to control for cellular DNR distribution differences and related differences in DNR fluorescence yield, whereas the radioactive method provides an absolute value in (f)mol DNR per cell. In addition we have applied a correction for the mean cell diameter in the sample, since this has been reported to improve correlations of DNR accumulation with resistance factors in cell lines. 27 Third, as measurement for the in vitro cytotoxicity of DNR a standardized MTT assay was used. This assay has been successfully used to predict clinical outcome in childhood leukemias. 6, 7 As far as its use in adult AML, two pilot studies have shown that in vitro resistance to DNR was significantly related to non-response, 28, 29 whereas in vitro resistance to cytarabine was associated with short and longterm outcome. 28, 29 Prospective studies addressing the clinical relevance of this assay are clearly needed. Fourth, we have given priority to the detection of the Mvp/LRP protein, because it has been reported to be of prognostic value in AML. 20, 30 Thus, since the purpose of this study was to clarify the relationship, if any, between a number of parameters, which supposedly predict the 'MDR status' of a leukemic sample, it was necessary to measure many parameters in the same samples. It is important to note that the different number of tests done for the various parameters was not based on a selection, related to the sample (such as for instance the number of cells available), but on practical circumstances such as the availability of manpower to perform the different tests.
Pgp activity, DNR accumulation and DNR LC 50
One conclusion from this study is that the Pgp activity in de novo AML blasts correlates with the steady-state DNR accumulation in the cells but not with the in vitro sensitivity to DNR LC 50 of the population of cells as measured by an MTT viability test after 72 h of drug exposure. Thus variations in other factors than Pgp activity or net DNR accumulation contribute more to the differences in the in vitro DNR LC 50 . This does not preclude some effect of blocking Pgp by coadministration with a 'resistance modifier' such as PSC833 on therapy outcome. Since the predictive value of the MTT test in adult AML still has to be established, a definitive assessment of a clinical benefit of blocking Pgp on leukemic cells must be obtained in (phase III) clinical trials with Pgp blockers. The present and our earlier data, 16 however, allow us to estimate the maximal effects to be expected by blocking Pgp on DNR accumulation and cytotoxicity of leukemic cells. This may facilitate the interpretation and mechanistic explanation of the results from ongoing clinical studies. In a previous study we calculated, based on 51 samples that the effect of blocking Pgp activity in AML would increase the intracellular DNR accumulation with about 50% (DNRratio = 1.5) at most.
14 In the present study the PSC833 effect on DNR accumulation (DNRratio) was measured in 140 de novo AML samples (see Table 1 ). The mean value was 1.08 (median 1.04) with 11 samples having a ratio of Ͼ1.25. Two samples had an effect above the previously estimated increase of 50%, namely a ratio of 1.79 and 1.90.
In this respect it is remarkable that a relatively large modulation effect was seen in some AMLs in the MTT test: up to a factor 5 to 6 increase in DNR cytotoxicity upon co-incubation with 2 m PSC833. We conclude that this effect cannot be explained exclusively by blocking Pgp activity. Also the effect of PSC833 on DNR cytotoxicity was unrelated to (a high) IC 50 for DNR (not shown). Others have reported that the effects of the Pgp modulator verapamil on doxorubicin in vitro cytotoxicity did not seem to be related to Pgp expression in AML. 31 The data that are lacking here in order to be able to draw a conclusion on the lack of correlation between Pgp activity and in vitro cytotoxicity is the relation between an MTT viability test and a clonogenic survival assay. Based on tumor cell line data, 32 even a small increase in Pgp expression should be expected to lead to less cytostatic effect of DNR. In accordance which these expectations, it has recently been shown that by using mdr1 antisense nucleotides the sensitivity of AML blast progenitors to DNR, measured in a colony assay, increased several-fold. 33 Therefore, in order to further our understanding of the potential of PSC833 to enhance the anthracycline cytotoxicity for AML blasts, its effect on clonogenic survival of leukemic cells in the presence of anthracyclines, parallel to a Pgp function test, may have to be determined. In addition, since in the present and most other studies only the mean of the fluorescence distributions are measured, future studies also should pay attention to the heterogeneity in expression of Pgp (function) and other resistance markers in AML.
Mvp/LRP expression and DNR accumulation and cytotoxicity
We have found no correlation of the expression of the Mvp/LRP protein with either Pgp function or DNR accumulation, or in vitro DNR cytotoxicity. First this shows that the two phenotypes 'LRP high' and 'Pgp high' are not necessarily co-expressed in adult AML and confirms and extends the results of two previous studies that both may have to be measured in order to increase the accuracy of the prediction of therapy outcome. 20, 30 The complete lack of correlation of Mvp/LRP expression with intracellular DNR accumulation is in agreement with the finding that in extremely high LRPexpressing renal cell cancer cell lines in a steady-state situation no gradient of extracellular DNR to cytosolic DNR concentration could be measured (Versantvoort and Broxterman, unpublished observations). This was interpreted as the absence of a significant outward active transport for DNR in these cells. Therefore, a causal, mechanistic relationship of Mvp/LRP with drug resistance is still lacking. Similar results have recently been reported for childhood acute lymphoblastic leukemia. 34 The prognostic significance of Mvp/LRP (alone or in combination with Pgp expression) for therapy outcome in AML is still controversial with reports showing data in favor 20, 30 and against 22 a role as independent prognostic factor.
In conclusion, the present paper provides new data on the relation between different drug sensitivity tests in adult de novo AML. Our result that Pgp activity did not predict the LC 50 for DNR are in agreement with Efferth et al, 18 who showed data suggesting that the MTT assay for DNR correlated better with apoptosis tests in AML than with Pgp-related tests. Depending on the particular test used, one may thus be able to assign the contribution of a particular resistance mechanism/protein to clinical outcome or establish a more general in vitro drug sensitivity profile. The finding that neither Pgp activity nor MRP1 expression, nor LRP expression correlate with in vitro cytotoxicity to DNR or the modulatory effect of PSC833 on DNR IC 50 must be interpreted with caution, as long as the clinical value of an in vitro MTT assay and its relationship to survival of clonogenic blast cells has not been established.
